Levofloxacina Combino (Levofloxacin)

Levofloxacin works by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes that are essential for DNA replication, transcription, and repair. This inhibition prevents the resealing of DNA strands, leading to bacterial cell death and providing broad‑spectrum antibacterial activity.

The dosage of Levofloxacina Combino is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Healthcare professionals calculate the appropriate infusion rate and total daily amount for each individual case.

Safety data for levofloxacin during pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Physicians should discuss the risk‑benefit profile with pregnant or nursing patients before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.

Levofloxacina Combino contains levofloxacin, which is the L‑isomer of ofloxacin and generally offers higher potency and better tissue penetration than older fluoroquinolones such as ciprofloxacin. It provides a broader spectrum against Gram‑positive organisms while maintaining activity against Gram‑negative pathogens, making it a preferred choice for many severe infections.

The product must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and used within the time frame recommended by the manufacturer.

Levofloxacina Combino is given by intravenous infusion. The infusion rate and duration are set by the prescribing clinician, typically over 30 minutes to 1 hour, depending on the infection severity and patient tolerance. Administration should follow aseptic technique and be monitored for any infusion‑related reactions.

Serious adverse events include tendon rupture (especially the Achilles tendon), QT interval prolongation leading to arrhythmias, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, peripheral neuropathy, and seizures in patients with pre‑existing CNS disorders.

Patients with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation should avoid the product. It is also contraindicated in individuals with a history of tendon disorders related to fluoroquinolone use, those with significant QT prolongation, and patients with severe renal impairment without appropriate dose adjustment.